Iatrogenic hypoglycaemia following glucose-insulin infusions for the treatment of hyperkalaemia

Simple item page
dc.check.date2021-09-26
dc.check.infoAccess to this article is restricted until 12 months after publication by request of the publisher.en
dc.contributor.authorTee, Su Ann
dc.contributor.authorDevine, Kerri
dc.contributor.authorPotts, Adam
dc.contributor.authorJavaid, Usman
dc.contributor.authorRazvi, Salman
dc.contributor.authorQuinton, Richard
dc.contributor.authorRoberts, Graham
dc.contributor.authorLeech, Nicola J.
dc.date.accessioned2020-10-01T11:02:07Z
dc.date.available2020-10-01T11:02:07Z
dc.date.issued2020-09-26
dc.date.updated2020-10-01T10:39:58Z
dc.description.abstractObjectives: To study the incidence of, and risk factors for, iatrogenic hypoglycaemia following GwI infusion in our institution. Context: Hyperkalaemia is a life‐threatening biochemical abnormality. Glucose‐with‐insulin (GwI) infusions form standard management, but risk iatrogenic hypoglycaemia (glucose ≤ 3.9mmol/L). Recently updated UK guidelines include an additional glucose infusion in patients with pre‐treatment capillary blood glucose (CBG) <7.0 mmol/L. Design: Retrospective analysis of outcomes for GwI infusions prescribed for hyperkalaemia from 1st January‐28th February 2019, extracted from the Newcastle‐upon‐Tyne Hospitals NHS Foundation Trust electronic platform (eRecord). Participants: 132 patients received 228 GwI infusions for hyperkalaemia. Main outcome measures: Incidence, severity and time‐to‐onset of hypoglycaemia. Results: Hypoglycaemia incidence was 11.8%. At least 1 hypoglycaemic episode occurred in 18.2% of patients with 6.8% having at least 1 episode of severe hypoglycaemia (<3.0 mmol/L). Most episodes (77.8%) occurred within 3 hours of treatment. Lower pre‐treatment CBG(5.9 mmol/L [4.1 mmol/L ‐ 11.2 mmol/L],; versus 7.6 mmol/L [3.7 mmol/L ‐ 31.3 mmol/L], p = 0.000) was associated with hypoglycaemia risk. A diagnosis of type 2 diabetes and treatment for hyperkalaemia within the previous 24 hours were negatively associated. Conclusions: Within our inpatient population, around 1 in 8 GwI infusions delivered as treatment for hyperkalaemia resulted in iatrogenic hypoglycaemia. Higher pre‐treatment CBG and a diagnosis of type 2 diabetes were protective, irrespective of renal function. Our findings support the immediate change to current management, either with additional glucose infusions, or by using glucose‐only infusions in patients without diabetes. These approaches should be compared via a prospective randomised study.en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationTee, S. A., Devine, K., Potts, A., Javaid, U., Razvi, S., Quinton, R., Roberts, G. and Leech, N. J. (2020) 'Iatrogenic hypoglycaemia following glucose-insulin infusions for the treatment of hyperkalaemia', Clinical Endocrinology. doi: 10.1111/cen.14343en
dc.identifier.doi10.1111/cen.14343en
dc.identifier.eissn1365-2265
dc.identifier.issn0300-0664
dc.identifier.journaltitleClinical Endocrinologyen
dc.identifier.urihttps://hdl.handle.net/10468/10618
dc.language.isoenen
dc.publisherJohn Wiley & Sons, Inc.en
dc.rights© 2020, John Wiley & Sons, Ltd. This is the peer reviewed version of the following article Tee, S. A., Devine, K., Potts, A., Javaid, U., Razvi, S., Quinton, R., Roberts, G. and Leech, N. J. (2020) 'Iatrogenic hypoglycaemia following glucose-insulin infusions for the treatment of hyperkalaemia', Clinical Endocrinology, doi: 10.1111/cen.14343, which has been published in final form at https://doi.org/10.1111/cen.14343. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.en
dc.subjectDextroseen
dc.subjectHyperkalaemiaen
dc.subjectHypoglycaemiaen
dc.subjectGlucose-with-insulinen
dc.titleIatrogenic hypoglycaemia following glucose-insulin infusions for the treatment of hyperkalaemiaen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
cen.14343.pdf
Size:
8.5 MB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
HRB Clinical Research Facility at UCC - Journal Articles